Introduction {#S1}
============

Mammalian Target of Rapamycin (mTOR) is a serine/threonine kinase that was discovered in the early 1990s as the target of the anti-fungal drug rapamycin ([@R1],[@R2]). mTOR signaling integrates a variety of environmental and intracellular cues to coordinate a number of cellular processes. The physiological relevance of mTOR signaling is vividly illustrated by the multitude of human diseases that can occur upon its deregulation, including cancer.

Cancer is a disease characterized by its hallmarks ([@R3]), including uncontrolled cell proliferation, increased cell survival, evasion of anti-tumor immunity, aberrant angiogenesis, and acquisition of metabolic events unique to cancers. Importantly, activation of mTOR signaling is associated with each of these oncogenic cellular processes, making mTOR a promising target for treating multiple hallmarks of the cancer phenotype.

The mTOR Complexes {#S2}
==================

Although rapamycin was originally defined as an anti-fungal agent, it was soon realized that rapamycin possesses broad anti-proliferative, cytostatic effects in a wide variety of cells, including cancer cells. Subsequent molecular analyses revealed that rapamycin binds to FKBP12, and in doing so, blocks some (but not all) mTOR activity. In searching for the molecular underpinnings of why rapamycin produced only partial mTOR inhibition, it was discovered that mTOR acts in two functionally distinct complexes ([@R4],[@R5]), one that is relatively sensitive to rapamycin (mTOR complex 1, or mTORC1), and one that is relatively rapamycin resistant (mTORC2) ([@R6]). Both mTORC1 and mTORC2 harbor several common components: the mTOR kinase, which acts as the central catalytic component, the scaffolding protein mLST8, mTOR regulatory subunit DEPTOR, and the Tti1/Tel2 complex, which is important for mTOR complex assembly and stability. Additionally, each complex harbors distinct subunits ([Figure 1](#F1){ref-type="fig"}) that contribute to substrate specificity, subcellular localization, and complex specific regulation. mTORC1 is defined by its association with Raptor, a scaffolding protein important for mTORC1 assembly, stability, substrate specificity, and regulation, and PRAS40, a factor that blocks mTORC1 activity until growth factor receptor signaling relieves PRAS40-mediated mTORC1 inhibition. The recently solved structure of mTORC1 shows that it acts as a lozenge shaped dimer with the kinase domains coming in close proximity to one another in the center of the structure and Raptor and mLST8 binding on the periphery ([@R7],[@R8]).

Rictor and mSin1 are subunits specific to mTORC2. Genetic engineering of cells deficient for Rictor demonstrate that Rictor is required for mTORC2 assembly, stability, substrate identification, and subcellular localization of mTORC2 to the appropriate sites of action ([@R4]). mSin1 is also required for subcellular localization of mTORC2 to the plasma membrane ([@R9]). Importantly, mSin1 is a key negative regulator of mTORC2 kinase activity, until growth factor receptor-derived signaling through the phosphatidylinositol-3-kinase (PI3K) recruits mSin1/mTORC2 to the plasma membrane, where Sin1-mediated mTORC2 inhibition is relieved. Although the structure of mammalian mTORC2 has yet to be resolved, cross-linking mass spectrometry and electron microscopy have been used to determine the architecture of TORC2 in yeast ([@R10]). The structure of TORC2 looks similar to that of TORC1, although TORC2 specific components bind to different locations along the TOR kinase. Since yeast has separate TOR kinases for each complex, solving the structure of mammalian mTORC2 is still an important goal that will lead to further understanding of mTORC2 function.

The differing components and structures of mTORC1 and mTORC2 allow for independent regulation through subcellular localization. For example, active mTORC2 associates closely with the plasma membrane, and has been detected in association with ribosomal membranes ([@R11]), where it can interact with its key substrates, the AGC kinases including AKT1-3, serum glucose kinase (SGK) isoforms, and protein kinase C (PKC) family members. In contrast, mTORC1 appears to be affiliated with endosomal and lysosomal membranes, where it interacts with its effectors 4EBP1 and S6K1 ([Figure 2](#F2){ref-type="fig"}).

mTORC1 Signaling {#S3}
================

The PI3K pathway is frequently activated in response to oncogenic growth factor receptor signaling. PIK3CA activating mutations, RAS mutations, or PTEN loss result in increased production of the second messenger phosphatidylinositol ([@R3],[@R4],[@R5])-triphosphate (PIP3) ([@R12]). Although PIP3 directly recruits and activates mTORC2, PI3K signaling also indirectly activates mTORC1, primarily through AKT. Activation of AKT occurs through phosphorylation at Ser473 mediated by mTORC2, and at T308 mediated by PDK1, another serine-threonine kinase recruited to the plasma membrane by PIP3. Once activated, AKT phosphorylates tuberous sclerosis complex 2 (TSC2), blocking its association with TSC1 ([@R13]--[@R15]). Since TSC1/2 is a negative regulator of the mTORC1 activator RHEB, AKT-mediated TSC2 phosphorylation allows GTP-loaded RHEB to bind and activate mTORC1 ([@R16],[@R17]). AKT also phosphorylates the mTORC1 inhibitor PRAS40, causing PRAS40 to dissociate from Raptor, permitting mTORC1 activation ([@R18]--[@R21]).

In addition to the PI3K pathway, the Ras-MAPK signaling cascade can activate mTORC1. Similar to AKT-mediated phosphorylation of TSC2, ERK and RSK also phosphorylate TSC2 ([@R22],[@R23]), albeit at different residues, to inhibit the TSC1/2 complex and trigger RHEB-mediated activation of mTORC1. Similarly, RSK can also phosphorylate PRAS40 ([@R24]), leading to dissociation from Raptor and promoting mTORC1 activation.

Although growth factor signaling through the PI3K/AKT and Ras-MAPK cascades is a key trigger for cellular proliferation, it is important that cells do not proceed with proliferation if the necessary nutrients, energy, and macromolecules are not available to support the high demands of cellular replication. Consistent with this notion, mTORC1 is highly responsive to intracellular ATP, glucose, and certain amino acids, including leucine, arginine and glutamine. Low ATP/high AMP levels activate AMP kinase (AMPK), an indirect mTORC1 inhibitor which functions by promoting TSC1/2 complex formation ([@R25]). Thus, AMP accumulation would override growth factor signals and block cellular proliferation in the absence of a sufficient energy supply. Similarly, a lack of amino acids would prevent localization of mTORC1 to lysosomal surfaces where RHEB activates mTORC1, overriding growth factor receptor-derived proliferation signals ([@R26],[@R27]), and blocking mTORC1-dependent proliferation in the absence of the needed supply of amino acids. Interestingly, the intracellular location and type of amino acid can be sensed by the cell to determine the mechanism by which mTORC1 lysosomal localization is regulated ([@R28]). For example, intralysosomal arginine ([@R29]) or cytoplasmic leucine ([@R30]--[@R32]) activates RAG-GTPases which associate with Raptor directly to localize mTORC1 to lysosomal membranes ([@R33]). Meanwhile, cytoplasmic glutamine regulates mTORC1 localization through RAG-independent mechanisms ([@R34],[@R35]).

Once activated, mTORC1 phosphorylates substrates, including elongation initiation factor (EIF)-4E binding protein 1 (4EBP1) and ribosomal protein S6 kinase 1 (S6K1), two proteins that are key regulators of both cap-dependent and cap-independent translation. Interestingly, increased cap-dependent translation caused by aberrant mTORC1 activation results in increases in cell size ([@R36]) and proliferation ([@R37]), two common traits of cancer. 4EBP1 and S6K1 bind to eIF-4E and eIF-3, respectively, inhibiting formation of the translation initiating complex. mTORC1-mediated phosphorylation of 4EBP1 and S6K1 liberates their respective binding partners, facilitating preinitiation complex formation ([@R38]). S6K1 phosphorylates eIF-4B and S6 ribosomal protein (S6RP), initiating translation ([@R39]). S6K1 also plays a key role in translational elongation, phosphorylating eukaryotic elongation factor 2 kinase (eEF2K), allowing eEF2 to continue translational elongation ([@R40]). Interestingly, mTORC1 does not affect all transcripts equally. For instance, prostate cancer studies showed that the most common targets of increased translation were those involved in invasion, metastasis, and protein synthesis, highlighting the role of mTORC1 in oncogenic translation ([@R41]). Increased translation of protein synthesis genes, consisting mostly of genes involved in ribosomal biogenesis ([@R42]--[@R44]), is a well-known phenomenon related to mTORC1 hyper-activation. This is a logical target for mTORC1-mediated oncogenic translation since sufficient ribosome levels are required to maintain the increased translation of other genes important for transformation.

mTORC1 in Cancer {#S4}
================

Direct evidence for mTORC1 activity in tumorigenesis comes from Tuberous Sclerosis, a disease caused by loss of TSC1 or TSC2, consequently hyper-activating mTORC1, and resulting in widespread but benign tumor formation. The limited progression of these tumors may be due to mTORC1-mediated negative feedback on insulin receptor substrate (IRS)-1, potently downregulating PI3K signaling downstream of most receptor tyrosine kinases (RTKs) ([@R45]--[@R47]). Also, mTORC1 directly phosphorylates Grb10, an adaptor that directly binds RTKs ([@R48],[@R49]), although Grb10 phosphorylation is reported to have the capacity to stimulate and block PI3K activation, perhaps in isoform-specific fashions. Regardless, tuberous sclerosis patients demonstrate that mTORC1 signaling as a single molecular aberration is a potent driver of cellular proliferation. In the context of added genetic and molecular alterations, mTORC1 signaling potentiates the severity of tumor progression through numerous molecular mechanisms.

Transformed cells display metabolic reprogramming, a requirement that may enable cancer to surmount the demands of rapid proliferation. For example, many tumors display aerobic glycolysis, in which glycolysis occurs in the presence of oxygen, perhaps not as a main source of ATP, but rather as a generator of building blocks that can be shunted to alternative anabolic pathways to generate molecules needed for proliferation, including lipids, amino acids, and nucleotides. There is evidence that mTORC1 regulates aerobic glycolysis through increased translation of hypoxia inducible factor (HIF)-1α ([@R50]), a transcription factor that drives expression of several glycolytic enzymes ([@R51]). mTORC1 upregulates the synthesis of lipids from glycolysis-derived intermediates through phosphorylation of Lipin1 and S6K1, thus activating the transcription factor sterol regulatory element binding factor (SREBP)-1, driving transcription of genes involved in lipogenesis ([@R52],[@R53]). Loss of mTORC1-mediated activation of SREBP1 in breast cancer cells blocked lipogenesis, interfering with cellular proliferation and tumor growth ([@R54]). Shunting of glycolytic intermediates into nucleotide synthesis is also controlled in part by mTORC1. mTORC1-mediated phosphorylation of S6K1 stimulates both purine and pyrimidine synthesis, which is necessary for cancer cells to rapidly duplicate their DNA ([@R55]--[@R57]).

These studies would suggest that targeted inhibition of glycolysis would be a feasible approach to blocking cell growth, despite mTORC1 activation. However, phase I clinical trials of the glycolysis inhibitor 2DG yielded disappointing results, with disease progression in the majority of cases, although a few showed stable disease or partial responses ([@R58]). Ovarian cancer cells cultured in 2DG to select for glycolysis resistance had upregulated mTORC1 activity as well as increased lipogenesis and nucleotide synthesis ([@R59]). These findings suggest that mTORC1-mediated glycolysis may support cancer cells, but that in the absence of glycolysis, other mTORC1-mediated anabolic pathways still support cell proliferation. However, how these tumor cells are supplied with the necessary intermediates for shunting into alternative metabolic pathways, but in the absence of glycolysis, is a question that remains.

Answers may be found in the ability of cells to upregulate macropinocytosis, the process used by cells to obtain macro-nutrients from the extracellular environment. mTORC1 negatively regulates lysosomal degradation of extracellular protein taken up by macropinocytosis. Experiments in which tumor cells were starved of amino acids in culture and in tumors that were poorly vascularized in vivo, demonstrated that mTORC1 inhibition provided a growth advantage, through upregulation of macropinocytosis and catabolism of engulfed proteins ([@R60]). The dual roles of mTORC1 in tumor metabolism and growth will need further consideration, particularly in patients treated with mTOR inhibitors.

Aside from regulating cell growth and metabolism, mTORC1 also controls autophagy, an intracellular process that allows orderly degradation and recycling of cellular components. mTORC1 negatively regulates autophagy by phosphorylation of ULK to block initiation of autophagy, VPS34 to block autophagosome formation ([@R61]). Autophagy is sometimes considered a tumor suppressor ([@R62]), since blockade of autophagy, through deletion of Beclin1 for example, promotes tumor formation ([@R63],[@R64]). However, there is abundant evidence to support that autophagy can be harnessed by tumor cells to drive survival under conditions of metabolic duress ([@R65]). In this scenario, inhibition of mTORC1 might enhance autophagy, and in doing so, may allow cells to generate nutrients and molecular building blocks to support tumor cell survival to a greater extent than if mTORC1 signaling was left intact.

mTORC2 Signaling {#S5}
================

Unlike mTORC1, the upstream regulation of mTORC2 is not well defined, although growth factor stimulation and ribosome association are both known mTORC2 activators ([@R11],[@R66]). Importantly, mTORC2 localization at the cell membrane through the mSin1 subunit places mTORC2 in close proximity to its substrates AKT, SGK, and PKC. Thus localization at the plasma membrane is a key aspect of mTORC2 regulation ([@R9]). An oncogenic mutation in the PH domain of mSin1 that blocks mSIN1-mediated mTOR inhibition leading to constitutive mTORC2-AKT signaling has been identified in an ovarian cancer patient ([@R9]). Direct phosphorylation of mSin1 at T86 by AKT may also regulate mTORC2, leading to a positive feedback loop that sustains mTORC2-AKT signaling, while mSin1 phosphorylation by S6K1 at this same site may inhibit mTORC2 activity as a feedback mechanism downstream of mTORC1 ([@R67]--[@R69]). Recent studies have identified another function for mSin1 in mTORC2 regulation. The PH domain of mSin1 can also bind to phosphorylated cytoplasmic Rb through to inhibit mTORC2 complex formation and reduce AKT signaling ([@R70]). Regulation of mTORC2 by mSin1 may be cell-type and/or context dependent. Clarification of these feedback mechanisms will be important for complete understanding of mTORC2 activation and signaling in cancer.

AKT, a key substrate of mTORC2, is among the most commonly hyper-activated proteins in cancer. AKT integrates signals from PI3K/mTORC2 and from PI3K/PDK1 to promote cell growth and survival. Like mTORC2, AKT localization to the plasma membrane is regulated by PIP3. In PTEN null prostate cancer, loss of mTORC2 activity inhibits tumorigenesis, illustrating the importance of mTORC2 signaling downstream of PIP3 ([@R71]). Interestingly, PTEN null glioma patients exhibit mTORC2-mediated chemotherapy resistance in an AKT independent manner ([@R72]), suggesting that inhibition of mTORC2 may be useful in treatment of patients with PTEN or PI3K mutations. mTORC2 also regulates cancer cells' preferential use of glycolysis for energy production through the AKT-independent acetylation of FoxO1/3 ([@R73]), demonstrating a mTORC2-mediated role in cancer metabolism. In addition to its activation by mTORC2, AKT activates mTORC1 signaling ([@R13],[@R21]), adding another layer of complexity to this signaling pathway.

mTORC2 also phosphorylates SGK and PKC family members. Activation of SGK3 is implicated in cancer particularly because of its ability to reinforce PI3K signaling through INPP4B ([@R74]). Importantly, SGK1 promotes resistance to chemotherapy ([@R75]) and AKT inhibitors ([@R76]). Substrates of SGK include both NDRG1 and FoxO family transcription factors, two factors that are not growth promoting under oxygen and/or nutrient replete conditions, but which can promote survival in response to oxygen or nutrient deprivation, or in response to PI3K inhibition ([@R75],[@R77]). NDRG1 is a potent suppressor of tumor cell invasion and metastasis, and is degraded in response to SGK-mediated phosphorylation.

PKC, which exists in several isoforms, is also known to be involved in tumorigenesis, although the exact role of each isoform has yet to be defined. Studies have shown that each isoform may work in a cell-type specific manner. In the mouse mammary gland, genetic disruption of Rictor blocked mTORC2-dependent ductal branching, and reduced motility, invasion, and survival of mammary epithelial cells. Importantly this was rescued upon reactivation of PKCα and its downstream effector, Rac1 ([@R78]). Although studied in the developmental setting, all of these phenotypes are known to be important in breast cancer metastasis, suggesting a role for the mTORC2/PKCα signaling axis in breast cancer as well.

mTORC2 in Cancer {#S6}
================

While mTORC1 is extensively studied in cancer, recent reports also demonstrate a distinct role for mTORC2 in prostate, breast, and lung cancer, glioblastoma, and T-cell acute lymphoblastic leukemia (T-ALL) ([@R71],[@R79]). Amplification of *RICTOR* was observed in non-small cell lung cancer patients ([@R80]), breast cancer ([@R81]), and in residual disease of triple-negative breast cancers treated with neoadjuvant chemotherapy ([@R82]), reinforcing the importance of mTORC2 signaling in cancer and as a potential target for inhibition. Rictor overexpression was also previously noted in gliomas, in which about 70% of patients have increased AKT activity ([@R83]). In HER2-positive breast cancer, enriched Rictor expression leads to hyper-activation of AKT and tumor progression. Knockdown of Rictor (but not Raptor) or treatment with mTORC1/2 dual kinase inhibitors (but not mTORC1-specific rapalogs) decreased AKT-mediated tumor cell survival and increased therapeutic tumor cell killing in cells treated with the HER2/EGFR tyrosine kinase inhibitor, lapatinib ([@R81]). Collectively, these data suggest a distinct role for mTORC2 in cancer.

mTOR Inhibitors for Cancer Therapy {#S7}
==================================

Rapamycin was the original mTOR inhibitor, which allosterically inhibits mTORC1 ([Figure 1](#F1){ref-type="fig"}), but not mTORC2. The yeast structure of TORC2 suggests the Rictor analog Avo3 may block FKBP12-rapamycin complex binding to the mTOR kinase, granting rapamycin insensitivity, although the lack of mammalian mTORC2 structure prevents confirmation of this mechanism in humans ([@R10]). Interestingly, prolonged treatment with rapamycin inhibits mTORC2 in certain cell types, suggesting a cell-type specific mechanism of regulation of mTORC2 ([@R84]). Rapamycin analogs ("rapalogs") have been developed ([Table 1](#T1){ref-type="table"}) with enhanced pharmacokinetic properties for more effective treatment of patients ([@R85]). The first rapalog, temsirolimus, was approved by the FDA in 2007 after it was shown to be effective in treating advanced renal cell carcinoma ([@R86]). Since then, everolimus, another rapalog, has been approved for treatment of several other cancers including breast, pancreatic, lung, and subependymal giant cell astrocytoma. Rapalogs most often cause disease stabilization rather than regression, consistent with the idea that mTORC1 is a driver of cellular proliferation, but not cell survival.

There are several potential reasons for the limited efficacy of rapalogs in treating cancer. First, inhibition of mTORC1 action on its substrates is incomplete. Inhibition of mTORC1 by rapamycin completely blocks the phosphorylation of S6K1, but phosphorylation of 4EBP1 is often only modestly inhibited ([@R87]). Since 4EBP1 regulates cap-dependent translation, it is possible that 4EBP1 is still able to translate proteins important in tumorigenesis. Additionally, inhibition of mTORC1 will release mTORC1-mediated restraints on PI3K/mTORC2/AKT signaling, resulting in resurgent AKT signaling, increased growth, and heightened cell survival ([@R88],[@R89]). mTORC1 inhibition may also cause increased cell proliferation within vascularly compromised tumor regions due to elevated micropinocytosis ([@R60]) of extracellular proteins or increased cell survival through enhanced autophagy ([@R65]).

Recent advances have been realized in ATP-competitive mTOR kinase inhibitors (TOR-KIs), which block mTOR catalytic activity, whether embedded within mTORC1 or mTORC2 ([Figure 1](#F1){ref-type="fig"}) ([@R87]). Preclinical testing of these inhibitors has shown complete 4EBP1 inhibition, with sustained repression of mTORC2-mediated AKT phosphorylation, resulting in superior tumor cell killing and growth inhibition as compared to rapalogs ([@R89]). mTOR kinase inhibitors are currently in Phase II clinical trials, after promising results in Phase I trials ([Table 2](#T2){ref-type="table"}) ([@R91],[@R92]). While partial responses and stable disease have been reported, toxicity and adverse side effects are still a concern.

Pre-clinical studies have identified mutations in both the kinase domain and FRB domain of mTOR that prevent binding of either rapalogs or ATP-competitive mTOR kinase inhibitors, leading to loss of efficacy and eventual resistance. Most recently, a third-generation mTOR inhibitor has been developed to overcome resistance to currently available inhibitors. This third-generation inhibitor has a bivalent structure consisting of a rapamycin-FRB binding element linked to a TOR-KI ([@R93]), so that when at least one half the ligand binds, the other half is in close proximity to the second binding site, overcoming point mutations that prevent binding of either drug alone. Even with development of third-generation mTOR inhibitors, concerns about toxicity remain. Additionally, mTORC1 inhibition, even within the context of mTORC2 inhibition, may promote tumor cell proliferation under nutrient-stressed conditions, as evidenced by the mutant KRAS pancreatic ductal carcinoma tumor model ([@R60]). Therefore, it will be important to investigate the impact of TOR-KIs on macropinocytosis and autophagy in distinct tumor types under both nutrient replete and deprived conditions.

Small molecular weight kinase inhibitors capable of simultaneous blockade of mTOR and PI3K have also been developed ([Table 2](#T2){ref-type="table"}). As expected, these inhibitors overcome the limitations of rapalogs and inhibit mTORC2-independent activation of AKT, while providing superior blockade of resurgent PI3K activity. Unfortunately, Phase I clinical trials using PI3K/mTOR dual kinase inhibitors revealed significant dose-limiting on-target toxicities ([@R94],[@R95]), consistent with the important roles these enzymes fulfill in homeostasis of healthy tissues and systemic metabolism.

There is significant interest in developing mTORC2 specific inhibitors that will leave the activities of mTORC1 intact. Selectively targeting the mTORC2 branch may avoid feedback loop inhibition caused by rapalogs, and may be particularly effective in vascularly compromised tumors under metabolic stress. As an added and important benefit, toxicities related to mTORC1 inhibition, including lesions within the oral mucosa, rash, and immune suppression, may also be reduced. Notably, genomic aberrations in Rictor and mSin1 have been identified in several tumor types ([@R9],[@R80],[@R81],[@R83]) and patients with these genetic alterations may benefit from an mTORC2 specific inhibitor.

mTOR in Vasculature {#S8}
===================

In addition to its essential role in tumor cells, mTOR signaling is critical in the tumor microenvironment (TME) ([Table 3](#T3){ref-type="table"}). For example, mTOR is key for tumor angiogenesis ([@R96],[@R97]), a well-studied hallmark of cancer. In response to oxygen and/or nutrient deprivation, tumor cells secrete factors that recruit new vessel formation to support the growing tumor. Blockade of tumor angiogenesis would effectively limit tumor growth. Additionally, tumor vessels provide a route for tumor cells to disseminate to distant sites; as such, blockade of tumor angiogenesis could be harnessed to prevent tumor metastasis.

Hypoxia in the tumor stimulates angiogenesis via HIF transcription factors. In some cases, oncogenic mTOR signaling can actively promote cap-dependent translation of HIF-1α ([@R98],[@R99]). HIF-1α activates expression of proangiogenic factors that are secreted by the tumor cell, including vascular endothelial growth factor (VEGF). VEGF binds to the VEGF receptors on the surface of vascular endothelial cells, to promote angiogenesis. Interestingly, loss of the mTORC1 negative regulator TSC1 from vascular endothelial cells drives proliferative lesions resembling lymphangiosarcoma, suggesting that mTORC1 is a dominant driver of endothelial cell proliferation([@R100]), although evidence suggests mTORC2 could also play a role in endothelial cell proliferation through downstream effector PKCα ([@R101]). TSC1-deficient lymphangiosarcoma formation was suppressed not only by rapamycin, but also was by inhibitors of VEGF, defining a mTORC1-VEGF feed-forward loop in the angiogenic process that drives endothelial cell proliferation, survival, and vascular assembly ([@R100]). Rapalogs have been successful in treating highly vascularized tumors like Kaposi's sarcoma and renal cancer.

Interest in mTORC2 activity in the tumor vasculature was initiated with the observation that mTORC2 loss from endothelial cells causes deficiencies in physiological vascular development ([@R102]). Importantly, mTORC2 signaling has been implicated in sprouting angiogenesis stimulated by VEGF ([@R103]) and CXCL12 ([@R104]), both factors secreted by tumor cells to promote a more favorable microenvironment. Downstream of mTORC2, aberrant AKT signaling within the vascular endothelium promotes the tortuous and leaky vascular structures often associated with tumors ([@R105]). AKT has also been shown to primarily regulate vascular endothelial cell assembly ([@R101]). FoxO1, a substrate of the mTORC2 effectors AKT and SGK, has also been implicated in endothelial cell viability ([@R106]), growth ([@R107]), and metabolism ([@R108]). Since AKT can also activate mTORC1, it is possible that mTORC2 may have regulatory functions in the autocrine VEGF signaling within the vascular endothelium ([@R100],[@R109],[@R110]).

The use of mTOR inhibitors in treating cancers has provided insight into the effects of these inhibitors on the tumor vasculature. Everolimus, like VEGF inhibitors, decreased the tumor vasculature associated with a variety of solid tumor cell lines. While VEGF inhibitors were more potent at blocking formation of new vessels, everolimus was effective at reducing the viability of existing vessels ([@R111]). Consistent with the ability of everolimus to impair the integrity of existing tumor vasculature, radiation therapy caused excess damage to vascular endothelial cells upon mTOR kinase inhibition ([@R112],[@R113]).

mTOR in Tumor Immunity {#S9}
======================

Along with the tumor vasculature, the immune system is another facet of the TME that supports tumor initiation, progression, and metastasis, as tumor cells must actively evade immune surveillance to prevent eradication by the host. Tumors often express immunosuppressive 'checkpoint' markers such as CTLA-4 and PD-L1/PD-L2, that anergize CD8+ T-cells that would otherwise mount a cytotoxic attack ([@R114]). Inhibiting these immune checkpoints allows cytotoxic CD8+ T-cell activation and anti-tumor immune responses. Anti-PD-1/PD-L1 therapy has been extraordinarily successful in the treatment of melanoma patients and is currently in clinical trials for many other types of cancer.

A recent study in non-small cell lung cancer cells demonstrated that hyperactivated AKT-mTOR signaling directly increases PD-L1 expression ([@R115]). Interestingly, melanoma tumors grown in immunocompromised mice still respond to anti-PD1 therapy, suggesting a tumor intrinsic role for these immune checkpoint molecules ([@R116]). Further investigation showed that PD-1:PD-L1 interaction on tumor cells signals through mTORC1 to promote tumor cell proliferation. Together, these data suggest combination of checkpoint inhibitors and mTOR inhibition may be more efficacious than either therapy alone.

mTOR signaling within the immune cells themselves also deserves scrutiny, since rapamycin was first used in the clinic as an immune suppressant in organ transplant patients. The role of mTOR signaling in determining the fates of helper T cells has been relatively well defined. mTORC1 activity is predominately associated with Th1 differentiation and anti-tumor immunity ([@R117]). Inhibition of mTORC1 using rapalogs or rapamycin encourages engraftment in organ transplant patients through inhibition of cytotoxic immunity, particularly through expansion of CD4+regulatory T cells (T~reg~) ([@R118]). In contrast to mTORC1, mTORC2 activity is often associated with immune suppressive Th2 phenotypes ([@R117],[@R119]). This is regulated by mTORC2 downstream effector, SGK, which when depleted, limits differentiation of Th2 CD4+ T-cells ([@R120]).

In addition to CD4+ T-cells, mTOR signaling also regulates CD8+ T-cell effector function and differentiation, both important processes for mounting an immune response towards tumor cells. The role of mTORC1 as a regulator of CD8+ T-cell effector function has been well-defined by genetic deletion of the mTORC1 suppressor TSC2 in T-lymphocytes which resulted in mTORC1 upregulation and profound CD8+ T-cell effector function ([@R121]). Conversely, the role of mTOR signaling in establishing CD8+ memory T-cells has yet to be clearly defined. Rapamycin treatment reduced mTORC1 activity and increased CD8+ memory T-cell formation ([@R122]). Contrarily, other reports suggest that memory T-cell formation is predominately regulated by the mTORC2 pathway, as demonstrated by an increase in memory T-cell formation upon genetic deletion of Rictor in T-lymphocytes ([@R121],[@R123]). This discrepancy may be explained by the ability for rapamycin to inhibit mTORC2 in certain cell types, which would confirm the role of mTORC2 as the predominant regulator of memory T-cell differentiation.

While the role of T-cells is currently most well-studied in terms of mTOR signaling and tumor immunity, there is also evidence that mTOR signaling plays a role in other immune cells that could be important in the tumor microenvironment. TSC2 deletion in myeloid lineages increased mTORC1 signaling and blocked differentiation of macrophages towards an M2 phenotype, the phenotype most closely correlating to pro-malignant and immune suppressive tumor-associated macrophages (TAMs) ([@R124]). Although the roles played by B cells in tumor immunity is less understood, it is known B-cells can promote inflammation and carcinogenesis, as well as regulate anti-tumor T-cell responses. mTOR signaling is implicated in physiological B cell maturation, survival and proliferation, suggesting a possible role for mTOR in antibody-mediated regulation of tumor immunity ([@R125]).

Conclusions and Future Directions {#S10}
=================================

Increasing investigations of mTOR signaling in cancer cells and throughout the complex TME has provided the platforms from which new studies will reveal a more refined understanding of mTOR within each tumor compartment, the distinct and intertwining roles of mTORC1 and mTORC2, and how this knowledge can be applied towards novel therapeutic strategies that will safely and effectively eradicate cancers. Although rapalogs and mTOR kinase inhibitors have been used to treat patients with mTOR-dependent cancers, they have also exposed deficiencies in our knowledge of mTOR signaling and its role in cancer. As more patients are treated with these drugs, it will be important to not only monitor changes in tumor size and progression, but changes to the vasculature and immune system as well. In addition, mTORC2 specific inhibitors might be explored for use both in the laboratory and clinical settings. Preclinical studies of mTOR kinase inhibitors exposed new mechanisms of action for mTORC1. We anticipate similarly serendipitous findings as studies place increasing focus on mTORC2.
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![Schematic representation of mTOR complexes\
mTORC1 consists of the mTOR kinase, mLST8, DEPTOR, Tti/Tel2, Raptor, and PRAS40. mTORC2 also shares the mTOR kinase, mLST8, Tti/Tel2, and DEPTOR, but contains unique components Rictor and mSin1. Rapamycin is a known allosteric inhibitor of mTORC1, while TOR kinase inhibitors (TOR-KIs) inhibit the activities of both complexes.](nihms811211f1){#F1}

![Overview of the mTOR signaling pathway\
mTOR signaling is activated by a variety of environmental cues including growth factors, high cellular energy, and amino acids. Growth factors activate both mTORC1 and mTORC2, through binding of receptor tyrosine kinases (RTKs) or G-protein coupled receptors (GPCRs) and activation of PI3K or Ras-MAPK signaling cascades. PI3K phosphorylates PIP2 to increase the amount of PIP3 in the membrane, allowing co-localization of AKT, PDK1 and mTORC2. PDK1 phosphorylates AKT at T308, while mTORC2 phosphorylates AKT at S473 for complete activation. AKT in turn activates mTORC1 by inhibiting TSC2, a GAP for RHEB, an activator of mTORC1. AKT phosphorylation of PRAS40 promotes its dissociation from mTORC1 for full activation. ERK and RSK, both part of the Ras-MAPK signaling pathway, can also inhibit TSC2 to activate mTORC1 or activate mTORC1 directly through phosphorylation of PRAS40. High ATP levels in the cell inhibit AMPK, an activator of TSC2, thereby increasing the activities of RHEB and mTORC1. Intra-lysosomal arginine and cytoplasmic leucine stimulate Rag-dependent localization of mTORC1 to the lysosome where RHEB can activate mTORC1. Cytoplasmic glutamine triggers lysosomal localization of mTORC1 through a Rag-independent mechanism. Downstream targets of mTORC1 include S6K1 and 4EBP1, while downstream targets of mTORC2 include AKT, PKC, and SGK. S6K1 inhibits PI3K, completing a negative feedback loop on AKT signaling.](nihms811211f2){#F2}

###### 

mTOR inhibitors approved by the FDA for cancer treatment

  Drug                             Date of approval                                                                              Cancer Type                      Therapeutic Condition   Marketed By
  -------------------------------- --------------------------------------------------------------------------------------------- -------------------------------- ----------------------- ----------------
  Rapamycin/Sirolimus (Rapamune)   5.29.2015                                                                                     Lymphangioleiomyomatosis         Monotherapy             Pfizer (Wyeth)
  Temsirolimus (Torisel)           5.30.2007                                                                                     Renal Cell Carcinoma             Monotherapy             Pfizer (Wyeth)
  Everolimus (Afinitor)            5.30.2009                                                                                     Advanced Renal Cell Carcinoma    Monotherapy             Novartis
  10.29.2010                       Subependymal Giant Cell Astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (TSC)   Monotherapy                                              
  5.5.2011                         Progressive Neuroendocrine Tumors of Pancreatic Origin                                        Monotherapy                                              
  7.20.2012                        Hormone Receptor Positive, HER2 Negative Breast Cancer                                        In combination with Exemestane                           
  8.29.2012                        Pediatric and Adult SEGA associated with TSC                                                  Monotherapy                                              
  2.26.2016                        Neuroendocrine Tumors of Gastrointestinal or Lung Origin                                      Monotherapy                                              

###### 

mTOR inhibitors currently in clinical trials

  Drug Target                Drug Name        Published Clinical Trial                                 Cancer Type                                                                            References         Active Clinical Trials[\*](#TFN1){ref-type="table-fn"}                                                    Combination Therapy
  -------------------------- ---------------- -------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------ --------------------------------------------------------------------------------------------------------- ---------------------
  mTOR kinase inhibitor      OSI-027          Phase I                                                  Advanced solid tumors                                                                  [@R129]                                                                                                                      
  AZD2014                    Phase I/II       Advanced solid tumors, clear cell renal cancer           [@R92],[@R130]                                                                         18                 PaclitaxelAZD5363SelumetinibPalbociclibfulvestrantrituximabanastrozoleolaparib                            
  AZD8055                    Phase I          Advanced solid tumors, lymphoma                          [@R91]                                                                                                                                                                                                              
  CC223                      Phase I          Advanced solid tumors, multiple myeloma                  [@R131]                                                                                2                  CC122 or CC292 +/− Rituxumab                                                                              
  MLN0128                    None available                                                                                                                                                   10                 PaclitaxelBevacizumabMLN1117Alisertib or Paclitaxel or Cetuximab or IrenotecanExemestane or Fulvestrant   
  PI3K/mTOR dual inhibitor   BEZ235           Phase I/II                                               Advanced solid tumors, transitional cell carcinoma, pancreatic neuroendocrine tumors   [@R132]--[@R134]   1                                                                                                         
  XL765/ SAR254409           Phase I          Advanced solid tumors, high-grade glioma, lymphoma       [@R95],[@R135]--[@R137]                                                                                                                                                                                             
  GDC0980                    Phase I/II       Advanced solid tumors, metastatic renal cell carcinoma   [@R138],[@R139]                                                                        2                  FulvestrantAbiraterone Acetate                                                                            
  PKI587                     Phase I          Advanced solid                                           [@R140]                                                                                3                  Carboplatin and paclitaxelDocetaxel or Cisplatin or DacomitinibPalbociclib and Faslodex                   
  GSK2126458                 Phase I          Advanced solid tumors                                    [@R141]                                                                                                                                                                                                             
  PF04691502                 Phase I/II       Advanced solid tumors, endometrial cancer                [@R94],[@R142]                                                                                                                                                                                                      
  SF1126                     Phase I          Advanced solid tumors, B-cell malignancies               [@R143]                                                                                1                                                                                                                            
  BGT226                     Phase I          Advanced solid tumors                                    [@R144]                                                                                                                                                                                                             

Data summarized from ClinicalTrials.gov

###### 

Function of mTORC1 and mTORC2 in tumor and endothelial cells

  Tumor Cell                                                                               Endothelial Cell                                                                      
  ---------------------------------------------------------------------------------------- ------------------------------ ------------------------------------------------------ -------------------------------
  **mTORC1**                                                                                                                                                                     
  Cell Size and Proliferation                                                              Refs. [@R36],[@R37]            Autocrine VEGF signaling through HIF-1 α translation   Refs. [@R100],[@R109],[@R110]
  Metabolic Reprogramming: glycolysis, glutaminolysis, nucleotide synthesis, lipogenesis   Refs. [@R50]--[@R57], [@R59]   Vessel Permeability                                    Ref. [@R101]
  Stimulation of Angiogenesis                                                              Refs. [@R97]--[@R99],          Cell Proliferation                                     Ref. [@R96],[@R100]
  **mTORC2**                                                                                                                                                                     
  Cell Survival                                                                            Ref.[@R71]                     Vessel Morphology and Permeability                     Refs. [@R101],[@R105]
  Metabolic reprogramming: glycolysis, hypoxic response                                    Refs. [@R73],[@R77]            Cell Proliferation and Vascular Assembly               Ref. [@R101]
  Chemotherapy Resistance                                                                  Ref. [@R75]                    Metabolic Activity                                     Ref.[@R106]--[@R108]
